SEC 13F Intelligence

Birchview Capital, LP / XLRN

Birchview Capital, LP’s Acceleron Pharma Inc Position

Does Birchview Capital, LP own Acceleron Pharma Inc (XLRN)? Not currently — the last reported position was 10.7K shares worth $2M in Q3 2021; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$2M
Q3 2021
Shares
10.7K
% of Portfolio
+1.25%
Quarters Held
12
position exited

Position History XLRN

Reported value by quarter
Q4 ’18: $813,000Q4 ’18Q1 ’19: $870,000Q2 ’19: $767,000Q2 ’19Q3 ’19: $738,000Q4 ’19: $990,000Q4 ’19Q1 ’20: $2MQ2 ’20: $2MQ2 ’20Q3 ’20: $2MQ4 ’20: $2MQ4 ’20Q1 ’21: $3MQ2 ’21: $2MQ2 ’21Q3 ’21: $2Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q3 202110.7K$2M+1.25%
Q2 202118.7K$2M+1.40%
Q1 202118.7K$3M+1.50%
Q4 202018.7K$2M+1.38%
Q3 202018.7K$2M+1.40%
Q2 202018.7K$2M+1.08%
Q1 202018.7K$2M+1.49%
Q4 201918.7K$990,000+0.72%
Q3 201918.7K$738,000+0.49%
Q2 201918.7K$767,000+0.47%
Q1 201918.7K$870,000+0.55%
Q4 201818.7K$813,000+0.77%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Birchview Capital, LP’s full portfolio or all institutional holders of XLRN.